Genmab — Earnings Release 2014

Feb 4, 2015

Company Announcement

-- Worldwide net sales of Arzerra™ in Q4 2014 totaled GBP 12.3 million
-- Full year 2014 net sales of Arzerra were GBP 54.5 million
-- Genmab royalty income is DKK 23 million for Q4 2014 and DKK 101 million for
the year

Copenhagen, Denmark; February 4, 2015 – Genmab A/S (OMX: GEN) announced today
that net sales of Arzerra (ofatumumab) during the fourth quarter of 2014 were
GBP 12.3 million (approximately DKK 116 million). This figure consists of net
sales in the US of GBP 5.9 million and in the rest of the world of GBP 6.4
million. Under the terms of the collaboration with GlaxoSmithKline (GSK),
Genmab expects to receive a royalty payment of approximately DKK 23 million.

Full year 2014 net sales of Arzerra totaled GBP 54.5 million (approximately DKK
503 million) worldwide, compared to GBP 74.9 million in 2013. The total
royalty income to Genmab for 2014 is approximately DKK 101 million.

During the second half of 2014, rest of world sales of Arzerra were impacted by
sales related to the supply of Arzerra for clinical trials run by other
companies. Sales were not impacted by clinical trial material sales during the
first half.

The conversion from GBP to DKK has been made using the Danish Central Bank
average rates for the respective quarters in 2014.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated human antibody therapeutics
for the treatment of cancer. Founded in 1999, the company currently has one
marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic
lymphocytic leukemia indications and daratumumab in late stage clinical
development for multiple myeloma. Additionally Genmab has a clinical pipeline
with both late and early stage programs, and an innovative pre-clinical
pipeline. Genmab's technology base consists of validated and proprietary next
generation antibody technologies - the DuoBody® platform for generation of
bispecific antibodies, and the HexaBody™ platform which creates effector
function enhanced antibodies. Genmab's deep antibody expertise is expected to
provide a stream of future product candidates. Partnering of selected
innovative product candidates and technologies is a key focus of Genmab’s
strategy and the company has alliances with top tier pharmaceutical and
biotechnology companies. For more information visit www.genmab.com

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™;
the DuoBody logo™; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody™
and UniBody®. Arzerra® is a registered trademark of the GSK group of companies.

Company Announcement no. 02
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark